

**BUSINESS ANALYSIS
FUNDAMENTALS-CW2**

MEDTRONIC

**SECTOR LEVEL CHALLENGES AND
PROPOSAL AND ROADMAP FOR
SUSTAINED COMPETITIVE
ADVANTAGE**

Submitted By: Joslin Gadde

Student ID: 20076078

Table of Contents

1. Introduction:	3
2. Micro & Macro Environment Analysis:	3
2.1 MACRO – Level Framework:	3
2.1.1 PESTEL Analysis on Medtronic	3
2.2 MICRO ANALYSIS FRAMEWORK:	5
2.2.1 TWOS MATRIX ANALYSIS on Medtronic	5
3. Business Sector Analysis	7
3.1 Porter's Five Forces Framework on Medtronic	7
3.2 Mendelow's Matrix for Stakeholder Mapping.....	11
3.3 ANSOFF Matrix on Medtronic	13
4. Business Proposal	14
5. Implementation Road Map	17
6. Conclusion:	21
References:	22

1. Introduction:

The aim of this report is to apply relevant micro, macro, and business sector-level theoretical frameworks such as PESTEL, TWOS Matrix, Porters Five forces & Mendelow's Matrix for Stakeholders, Value Chain Analysis and many more to analyse Medtronic's strategic positioning within the global healthcare technology industry. This analysis seeks to evaluate how the company interacts with its organizational environment, identify current challenges and opportunities, and propose strategies that enable Medtronic to achieve sustained competitive advantage in an evolving market landscape.

2. Micro & Macro Environment Analysis:

Objective: The objective of this analysis is to examine how Medtronic interacts with its organizational environment by applying relevant theoretical frameworks. This involves using both micro-level (industry and stakeholder-focused) and macro-level (external environment-focused) analytical tools to evaluate the factors influencing Medtronic's operations, competitive positioning, and strategic decisions.

2.1 MACRO – Level Framework:

2.1.1 PESTEL Analysis on Medtronic

As a multinational corporation, Medtronic operates in a complex global environment where various factors influence its strategies and decision-making processes. These factors vary significantly across countries due to differences in laws, regulations, economic conditions, cultural attitudes, environmental, social, and technological advancements (Nielsen, 2019). The company must continuously monitor and adapt to these elements to remain competitive and compliant in diverse markets.

Supportive government healthcare policies and the growing demand for medical devices are strengthening the market position for Medtronic. An aging global population (Holland and Bátiz-Lazo, 2004) continues to increase the need for advanced medical technologies, while integration of AI in diagnostics creates new opportunities for innovation. Governments are prioritizing healthcare accessibility, particularly in developed and aging societies, which directly expands the market for medical solutions.

Economically, slow global medical market growth (Carter, 2018) is restricting expansion, while supply chain disruptions and sustainability pressures (Siddiqui, 2021) challenge operational resilience. External shocks such as pandemics, raw material shortages, and sustainability mandates affect production costs and delivery reliability. These pressures are compounded by healthcare cost constraints worldwide. Building resilient supply chains and embedding sustainability across operations is not optional—it is critical for maintaining long-term profitability and global reputation.

Social factors such as demographic trends, particularly the aging global population, are critical for market expansion. By 2050, approximately 16% of the world's population—around 1.5 billion people—will be aged 65 or older, increasing demand for advanced healthcare solutions. Medtronic's cardiac and diabetes technologies are well-positioned to address age-related and chronic conditions. Additionally, societal expectations for affordable and equitable healthcare, coupled with technological disruption from competitors, intensify pressure on the company to innovate continuously (Andolina, Gavioli & Ancarani, 2023).

Technological factors Within the landscape, Medtronic seeks to grow its market share by addressing gaps in high-tech medical devices. Its dual approach combines strategic acquisitions with sustained R&D investment, allowing the company to remain at the forefront of surgical and medical device innovation. Medtronic's strategy relies on advancing surgical and medical device technologies through continuous R&D. Integration of AI and digital health solutions is a major trend influencing Medtronic's future direction (Medtronic, 2025).

Environmental Factors that are expecting Medtronic to grow and adopt sustainable practices and reduce emissions and minimize the medical waste in the device manufacturing factory. Healthcare sector pressures require balancing technological progress along with environmental responsibility. (Hovelling et al.,2024).

Top 15 Largest Medical Device Companies in the World for 2024

Ranked by revenue from medical device sales



Created by
 **GetReskilled**

Data Source: Company Annual Reports 2023

Figure 1: Top Global Medical Equipment Companies in 2024

Legal factors that were obstacles to production were promptly addressed. Regulatory requirements were leveraged to aid production, and adaptability was necessary to navigate these challenges, with support from Medtronic's government affairs team, such as engaging with public authorities. (Fox et al., 2024). FDA approval processes and regulations for medical devices, MDR compliance in Europe, laws governing product safety and labelling, adherence to health and safety standards for employees and customers, and the impact of healthcare reimbursement policies like Medicare and Medicaid on market access and strategy

2.2 MICRO ANALYSIS FRAMEWORK:

2.2.1 TWOS MATRIX ANALYSIS on Medtronic

The TWOS Matrix is used for strategic alignment in an industry; based on the evaluations on its strengths, weakness and

opportunities it can turn up for growth rate and threats it can overcome, mostly balancing its internal challenges and the external capabilities.

Medtronic can leverage its strengths to capitalize on opportunities by utilizing its robust R&D capabilities to expand into new regions and grow its home care chronic device offerings (Nielsen, 2019).

Strength-Opportunities (SO): -

Medtronic can leverage its strong R&D capabilities not only to expand into new regions but also to enter the fast-growing surgical robot segment, positioning itself at the forefront of emerging medical technology markets. Its financial stability allows the company to pursue strategic global acquisitions, such as in cardiovascular care, which can enhance its product portfolio and market presence. (Nielsen, 2019). Furthermore, by combining innovation with rising population health demands, Medtronic can develop home-based chronic care devices, creating a differentiated value proposition that meets both patient needs and long-term market growth, while reinforcing the company's reputation as an industry leader in patient-centred solutions. (Wu and Luo, 2010).

Weakness -Opportunities (WO): -

To address internal fragmentation, Medtronic can restructure global operations by separating units to reduce complexity, sharpen focus, and prioritize core sectors. Strengthening product promotion alongside its R&D capabilities can boost visibility and adoption (Dargahi, Darrudi and Zalvand, 2019). By converting weaknesses into strategic enablers, Medtronic can enhance competitiveness, improve coordination, and ensure innovation delivers measurable market impact in fast-evolving healthcare segments.

Strengths -Threats (ST): -

Medtronic can optimize supply chains and expand manufacturing across multiple locations, leveraging its global positioning to reduce exposure to regional disruptions and geopolitical risks (Chaudhuri, 2015). By capitalizing on innovation leadership, the company can set new industry standards, thereby mitigating competitive pressures and regulatory

uncertainties (Nze-Ekpebie and Udealor, 2023). These strategies not only protect Medtronic from external threats but also reinforce its market influence, ensuring resilience in times of crisis and maintaining its reputation as a pioneering medical technology provider.

Weakness -Threats (WT): -

Medtronic should monitor and adapt to changing treatment protocols, regulatory requirements, and market dynamics to prevent internal weaknesses from being exacerbated by external threats. (Bajada et al., 2015). Developing flexible product strategies allows the company to pivot quickly in response to unforeseen situations, such as supply chain disruptions or sudden shifts in patient demand (Carter, 2018). By embedding adaptability and contingency planning into its operations, Medtronic can safeguard long-term performance, maintain customer trust, and ensure continuity in critical healthcare solutions during future crises.

3. Business Sector Analysis

3.1 Porter's Five Forces Framework on Medtronic

To remain competitive, Medtronic must develop a clear understanding of industry dynamics and the external pressures shaping the medical device sector. Porter's Five Forces framework examines the external market influences arising from potential new entrants, substitute products, shifting customer demands, supplier dynamics, and competitive rivalry that collectively shape the business environment of the organization under study (Nielsen, 2019). As Holland and Bátiz-Lazo (2004) and Scott Morton (1997) highlight, competitive forces play a decisive role in shaping how firms in healthcare and pharmaceuticals position themselves in the global marketplace, reinforcing the importance of strategic alignment with evolving industry conditions.

1. Threat of New Entrants (Moderate):

The moderate threat of new entrants implies that while barriers such as high capital requirements, regulatory approvals, and manufacturing complexities restrict market access, opportunities still exist for technologically advanced or well-financed firms to enter. Established companies, therefore, cannot remain complacent and must continue investing in innovation and compliance to maintain their competitive edge (Scott Morton, 1997). The presence of such barriers also highlights the

importance of intellectual property rights and patents as strategic tools to protect market positions.




Figure 2: Healthcare Market Size 2024-2034 (USD Billion)

2. Bargaining Power of Buyers (Low):

Buyer power in Medtronic's case is limited due to its unique position as the sole producer of the Micra leadless pacemaker. While patients, insurers, and healthcare providers typically influence pricing and product adoption, Medtronic's innovation reduces their leverage (Shaygan et al., 2017). However, the availability of conventional pacemakers as cost-effective alternatives, along with factors such as switching costs and demand for dual- versus single-chamber implants, prevents complete dominance. Overall, buyer bargaining power remains low, posing minimal risk to Medtronic.

3. Bargaining Power of Suppliers (High):

Despite a broad and global supplier base, Medtronic faces high supplier power due to reliance on specialized and critical components for devices such as the Micra pacemaker. Switching suppliers incurs significant costs, and the risk of forward integration—where suppliers of essential components may become competitors—further heightens vulnerability (UK Essay, 2013). This implies that careful supplier management and strategic partnerships are crucial to mitigate production disruptions and maintain

competitive advantage. According to Bloomberg, below is the list of suppliers of Medtronic (Parker, T., Medtronic)

Table 1: Supplier list of Medtronic

Supplier	Type	Region	Role in Medtronic's Supply Chain
Plexus Corp	Electronics Manufacturer	North America	Provides electronic manufacturing services for medical devices.
IntriCon Corp	Medical Device Manufacturer	North America	Supplies miniature medical components and devices.
Dassault Systèmes SE	Software Provider	Europe	Offers 3D design and simulation software for product development.
Celestica Inc.	Electronics Manufacturer	North America	Manufactures complex electronics and provides supply chain solutions.
Benchmark Electronics	Electronics Manufacturer	North America	Provides integrated electronics manufacturing services.
LISI	Components Supplier	Europe	Supplies precision components for medical devices.
TTM Technologies	Electronics Manufacturer	North America	Manufactures advanced printed circuit boards and interconnect solutions.
Vishay Inter technology	Component Supplier	Global	Provides electronic components like resistors and capacitors.
Microchip Technology	Semiconductor Supplier	Global	Supplies microcontrollers and analog semiconductors.
Berry Global Group	Packaging Supplier	Global	Provides medical packaging solutions.
Surmodics Inc.	Medical Device Supplier	North America	Supplies drug delivery and diagnostic components.
Varex Imaging Corporation	Imaging Components Supplier	North America	Provides X-ray imaging components.
Sinbon Electronics	Electronics Manufacturer	Asia	Manufactures interconnect solutions for medical devices.
COSMO Pharmaceuticals	Pharmaceutical Supplier	Europe	Supplies active pharmaceutical ingredients and finished dosage forms.

4. Threat of Substitute (Low): -

Medtronic faces a moderate to low threat from substitutes as competitors expand their portfolios and alternative medical products increasingly influence pricing. Although Medtronic's devices are highly specialized and supported by patents and expert sales representatives, the presence of alternative solutions in hospitals and healthcare systems means that price and perceived value could shift demand. This implies that Medtronic must continue investing in research and development and strategic acquisitions to differentiate its products, maintain quality leadership, and reduce the risk of customers switching to substitute therapies or devices.




Figure 3: First Quarter Final Results 2024 Fiscal Year Summary


5. Competitive Rivalry (High): -

Competitive rivalry is intense in the pharmaceutical industry, largely due to the presence of numerous global players competing for market dominance. High fixed operational costs, such as those associated with R&D, production, and compliance, force firms to aggressively compete to maintain profitability. Moreover, the need for continuous innovation to address evolving medical needs and patent expirations drives substantial investments in research and development. This dynamic environment intensifies competition and creates pressure for companies to differentiate

themselves through product pipelines, marketing strategies, and technological advancements.

Leading medical technology companies worldwide based on revenue in 2021 (in billion U.S. dollars)

Medical technology - top companies based on revenue 2021



source: Statista

Figure 4: Leading medical technology Companies worldwide based on revenue in 2021(in billions U.S. Dollars)

3.2 Mendelow's Matrix for Stakeholder Mapping

Medtronic operates within a complex healthcare service ecosystem, where multiple stakeholders interact with varying levels of power, legitimacy, and urgency. According to Wu et al. (2019), stakeholders in healthcare can be grouped into leading, core, and supporting populations, each influencing healthcare outcomes differently.

Key Players -Leading stakeholders (high power, legitimacy, urgency):

Regulatory authorities such as the FDA and EMA, along with hospital administrators and physicians, hold the greatest influence. They shape Medtronic's market access through compliance, approvals, and adoption decisions, playing a decisive role in integrating medical technologies into clinical practice (Wu et al., 2019).

Keep Informed -Core stakeholders (moderate-to-high influence):

Hospitals, rehabilitation institutions, and nursing homes are central to Medtronic's ecosystem since they implement devices like pacemakers, insulin pumps, and surgical robotics. Medical insurers and health departments are also critical, as reimbursement and policy frameworks directly affect affordability and demand (Rizk et al., 2021). Patients and family members, while traditionally passive, are increasingly active stakeholders, particularly in chronic disease management and shared decision-making. Research centres and independent laboratories further contribute to Medtronic's innovation and evidence-building collaborations (Wu et al., 2019).

Keep Satisfied -Supporting stakeholders (lower power but enabling):

Medical equipment suppliers, pharmaceutical partners, pharmacies, and digital payment platforms provide necessary infrastructure and services that enable Medtronic's value chain (Nielsen, 2019). Emerging actors such as health managers, online doctors, and digital hospitals are gaining relevance as digital health and remote monitoring expand, aligning with Medtronic's strategy of advancing precision medicine and integrated care (Wu et al., 2019).

Minimal Effort – Low Power and Low Interest

The wider community, public, and peripheral service providers (e.g., third-party payment platforms or small local suppliers) represent this group. (Rizk et al., 2021). While they have minimal direct influence over Medtronic's operations, their expectations regarding **corporate social responsibility (CSR), sustainability, and ethical practices** are increasingly shaping brand perception and long-term legitimacy. These groups may remain in a low-engagement position but can become more influential during crises or public debates around health equity and access (Wu et al., 2019).

Overall, Medtronic's success depends on actively managing leading stakeholders to ensure compliance and clinical adoption while fostering strong partnerships with core and supporting stakeholders to drive innovation, affordability, and patient trust. By taking a healthcare ecosystem approach, Medtronic can co-create value across micro (patients, physicians), meso (hospitals, insurers), and macro (regulators, digital health policy) levels, consistent with the dynamics highlighted by Wu et al. (2019).

Table 2: Classification results of stakeholders

Category	Stakeholders
Core stakeholders (22)	Physician; National Regulatory Authorities, Hospital Administrators Tertiary Hospitals, Pharmacists; Secondary Hospitals, Rehabilitation Institutions; Nursing Homes, Hospices, Nursing Staff; Community Service Centres, Contracted Medical Care Groups, Family Pension Groups, Family Doctors, Rehabilitation Physicians; Medical Research Centres, Independent Medical Laboratories; Medical Insurance Companies, Medical Insurance Department, Grassroots Regulatory Department; Patients, Family Members
Potential stakeholders (9)	Health Manager; Physician Medical Groups, Digital Hospital, Online Doctors; Medical Equipment Companies, Pharmaceutical Companies, Pharmacies; Third-Party Payment Platforms, Banks

3.3 ANSOFF Matrix on Medtronic

The Ansoff Matrix offers Medtronic a clear framework to defend core markets while pursuing new opportunities through product innovation, market expansion, and diversification. This approach aligns with Medtronic's global reach, strong partnerships, and innovation pipeline. As highlighted by Siddiqui (2021) and earlier strategy literature (Ansoff, 1957; Johnson et al., 2017), it provides a practical tool for navigating healthcare complexities and sustaining competitive advantage.

Market Development—the strategy of introducing existing products into new markets—represents a key positioning for Medtronic as a global healthcare technology company. The firm has pursued targeted marketing campaigns to expand its presence in emerging healthcare markets and strengthen international demand. Forecasts indicate that Medtronic aims to generate approximately \$15.3 billion in revenue from global markets by 2025 (DCF Modelling, 2024), supported by the identification of over 3,500 potential new hospital network partnerships across developing regions (Medtronic, 2024). This commitment has been underpinned by significant investment, including \$2.1 billion allocated to international market

expansion in 2022 (Medtronic, 2024). Such initiatives reflect Medtronic's strategic emphasis on scaling its existing portfolio globally while leveraging healthcare partnerships to extend accessibility, thereby aligning with its mission to advance medical technology worldwide.




Figure 5: Ansoff Matrix

4. Business Proposal

Proposed Business Initiative - Digital Health Ecosystem Platform for sustained competitive advantage.

Platform Concept:

Medtronic seeks to reposition itself at the forefront of digital health by developing a personalized, patient-centric healthcare monitoring platform designed to support long-term sustainability through proactive and preventive models of care. The platform focuses on individual healthcare monitoring with a personalized, patient-centric vision aimed at ensuring long-term sustainability (Benis et al., 2021). By leveraging advanced data analytics and connected health devices, the platform enables continuous monitoring of patients' health, promoting proactive care and early intervention. Furthermore, the integration of explainable artificial intelligence (AI) supports healthcare providers in making fair, accurate, and

reliable decisions, enhancing both patient safety and trust in digital healthcare systems (Hasan et al., 2023). This combination of personalized monitoring and transparent AI forms the core of a sustainable healthcare ecosystem that is responsive to individual patient needs.

Strategic Objectives:

Medtronic's strategic objectives align closely with the Ansoff Matrix. The strategic objectives of this platform are multi-faceted. Firstly, it aims to expand market share by 20% by 2030 through the provision of integrated healthcare solutions that combine medical devices, data analytics, and digital services. Additionally, the platform seeks to enhance global brand recognition, positioning the organization as a leader in digital healthcare innovation (Hasan et al., 2023). Another critical objective is to create new revenue streams through subscription-based digital health services, which will allow the organization to diversify its income sources while delivering continuous value to patients and healthcare providers (Mauro et al., 2024).

Competitive Advantage:

The platform's competitive advantage is grounded in its strong business continuity and sustained market position, underpinned by reliable data integrity and secure information management (Chotia et al., 2023). Moreover, the organization aims to maintain technology leadership within the healthcare sector by fostering collaborative ecosystems that connect healthcare providers, patients, and technology partners. These collaborations enable innovation, accelerate service delivery, and strengthen the organization's position in an increasingly competitive and digitally driven market.

Strategic Approach:

To ensure successful adoption of the platform, targeted training programs for healthcare professionals are a core strategic approach. Research indicates that approximately 70% of potential customers prefer to engage with companies through informative content rather than promotional messages, highlighting the importance of educational initiatives. In addition, the platform emphasizes accessibility for all, implementing localized affordability models in emerging markets through tiered pricing and collaborations with NGOs. This approach ensures equitable access to healthcare technologies and expands the platform's reach across diverse socioeconomic segments.

Revenue Enhancements & Benefits:

The platform enables Medtronic to transition from being solely a medical device manufacturer to a comprehensive healthcare solutions ecosystem leader. By integrating devices, data analytics, and digital services, the organization can enhance operational efficiency, reduce costs, and improve overall financial management (Fan et al., 2024). This transformation ultimately increases financial flexibility, allowing the enterprise to reinvest in innovation, expand its service offerings, and deliver sustained value to patients, providers, and stakeholders.

Table 3 : Medtronic Digital Initiatives Driving Growth (FY2025–FY2026)- Self Created

Growth Area	Key Metrics & Achievements
Cardiac Ablation Solutions	Revenue ↑ 50%; U.S. sales ↑ 72% due to innovations like pulsed field ablation technology
Diabetes Business	Q4 FY2025 revenue: \$728M; YoY growth: 10.4% (strong demand for diabetes management solutions)
Operational Efficiency	Operating profit ↑ 13%; Operating margin ↑ 70 basis points (Q1 FY2026)

Medtronic Digital Initiatives Contribution (Relative Scale)




Figure 6: Medtronic Digital Initiatives Contribution

Financial Flexibility through Digital Transformation:

Digital transformation enhances Medtronic's financial flexibility by streamlining financial processes and improving resource management. Advanced financial management systems and intelligent analytics enable accurate, timely financial insights and improved forecasting, reducing costs and uncertainty (Yi et al., 2023; Wei et al., 2022; Chen et al., 2015).

Furthermore, transforming key business operations fosters management reform and accelerates innovation. Data-driven decision-making allows Medtronic to adopt superior business models, reduce information and management costs, and strengthen financial performance and competitive advantage (Mikalef and Pateli, 2017; Chen et al., 2021; Theiri and Hadoussa, 2023).

Enhanced financial flexibility also supports healthcare equity. Cost-efficiency gains free up resources for medical devices, training, and service expansion, improving service quality and accessibility. Additionally, improved profitability and optimized fund allocation ensure full utilization of medical resources, enhancing patient satisfaction and healthcare provision balance (Ledley et al., 2020).

5. Implementation Road Map

The implementation of Medtronic's AI-driven healthcare solutions will be executed over a 24-month strategic timeline, divided into four critical phases.

Planning and Design (1-3 Months)

The first phase, spanning the initial one to three months, focuses on planning and design. During this period, Medtronic will develop a comprehensive AI solution framework, define the overall system architecture, and establish structured implementation protocols. This foundational stage ensures alignment between business objectives, technological capabilities, and regulatory requirements while laying the groundwork for a scalable and sustainable healthcare ecosystem.

Technical Integration (4-8 Months)

The second phase, covering months four through eight, emphasizes detailed system design, architectural development, and technical

integration. Medtronic will leverage its global network of 3,500 hospital partnerships to gather robust datasets for AI training and optimization (Medtronic, 2024). This phase also prioritizes interoperability across platforms, seamless data flow, cybersecurity compliance, and infrastructure readiness to enable enterprise-wide AI deployment.

Pilot implementation (9-15 Months)

During the third phase, from months nine to fifteen, the AI solution will undergo pilot implementation within selected hospital networks to validate performance in real-world settings. Medtronic will deploy training infrastructure to accelerate adoption among healthcare professionals while simultaneously executing marketing campaigns and awareness initiatives to engage stakeholders and communicate the solution's value. Co-development partnerships with technology and healthcare collaborators will be formalized to drive innovation and facilitate knowledge transfer. Iterative testing and feedback collection during this stage will ensure that the AI system meets performance, safety, and scalability standards.

Global Implementation (16-24 Months)

The final phase, spanning months sixteen to twenty-four, focuses on global implementation and market expansion. Medtronic will extend the AI solution to new international markets, maintaining a 24/7 responsive operational model to ensure consistent service quality (Medtronic, 2025). The organization will deploy AI-enabled medical devices at scale while ensuring regulatory compliance, operational excellence, and patient-centric care. This phase will maximize market penetration, reinforce competitive advantage, and position Medtronic as a global leader in AI-driven healthcare solutions.

By following this structured roadmap, Medtronic anticipates seamless integration of AI technology across its operations, accelerated adoption through targeted training and partnership initiatives, and enhanced operational efficiency and scalability. The strategic implementation will ultimately strengthen Medtronic's market leadership and deliver broad, sustainable value to healthcare providers and patients worldwide.

Medtronic AI-Driven Healthcare Solutions

Strategic Implementation Roadmap



Risk Mitigation:

The company faces several strategic risks that require proactive mitigation. Cybersecurity threats can compromise sensitive healthcare data; to address this, investing in robust cybersecurity frameworks is essential (Chotia et al., 2023). Competitive pressures from industry rivals such as J&J, Abbott, and Stryker necessitate differentiation through AI-driven innovation and stronger strategic partnerships. Resistance to adoption among healthcare providers can be mitigated by establishing training centers, offering incentives, and engaging in co-development partnerships to facilitate integration. Additionally, high R&D costs and uncertain returns on investment can be managed by implementing a stage-gate investment model and prioritizing scalable platform solutions to optimize resource allocation and accelerate value creation.

Risk Analysis:

Risk	Impact	Mitigation Strategy
Regulatory barriers in emerging markets	High	Build strong local compliance teams, collaborate with regulators early.
High R&D costs & uncertain ROI	Medium	Stage-gate investment model, focus on scalable platforms first.
Cybersecurity threats in digital health platforms	High	Invest in robust cybersecurity frameworks (Chotia et al., 2023).
Competition from rivals (Johnson & Johnson, Abbott, Stryker)	High	Differentiate via AI-driven innovation and stronger partnerships.
Adoption resistance from healthcare providers	Medium	Training centers, incentives, and co-development partnerships.

Metrics & KPI:

International revenue growth (Target: \$15.3 billion by 2025) (Medtronic, 2025a).

Clinical trial success rate for new technologies compared to industry benchmarks (Wu and Luo, 2010).

Supply chain resilience score (measured by on-time delivery >95%) (EY, n.d.; Banga, 2024).

Customer satisfaction (Net Promoter Score, NPS > 70) across global markets (Andolina et al., 2023).

Annual revenue growth rate (Target: 6–8% CAGR by 2028) (Medtronic, 2025b).

Business continuity readiness index, ensuring supply stability and resilience (Fan et al., 2024).

6. Conclusion:

The analysis highlights that Medtronic's sustained competitive advantage is closely tied to its capacity to align innovation, stakeholder management, and global expansion with the dynamic conditions of the healthcare industry. Both micro- and macro-environmental frameworks reveal that the organization operates in a landscape shaped by regulatory compliance, technological disruption, demographic shifts, and sustainability imperatives (Nielsen, 2019). The proposed digital health ecosystem supports Medtronic's strategic shift from being primarily a medical device manufacturer to a holistic healthcare solutions provider, thereby creating new revenue streams while reinforcing its patient-centric mission (Hasan et al., 2023).

Moreover, the structured implementation roadmap demonstrates the firm's commitment to resilience, scalability, and global compliance, ensuring operational continuity in the face of market and regulatory uncertainties (Chotia et al., 2023). By embedding adaptability and sustainability into its strategy, Medtronic strengthens its financial flexibility and long-term value creation, balancing profitability with healthcare equity (Ledley et al., 2020; Yi et al., 2023). Ultimately, Medtronic's forward-looking approach reflects a robust integration of business innovation and healthcare imperatives, positioning it to deliver enduring value to patients, providers, and shareholders while consolidating its role as a global leader in healthcare technology (Andolina, Gavioli & Ancarani, 2023).

References:

- Medtronic. (2025). Key Facts. Available at: <https://www.medtronic.com/uk-en/our-company/key-facts.html> [Accessed 29 July 2025].
- Pharmaceutical Technology. (n.d.). Medtronic Plc. Available at: <https://www.pharmaceutical-technology.com/contractors/pharma-logistics-supply-chain/medtronic-plc/> [Accessed 29 July 2025].
- Carter, J., 2018. A Strategic Audit of Medtronic PLC.
- Nielsen, C., 2019. Valuation of the company Medtronic.
- Holland, S. and Bátiz-Lazo, B., 2004. The global pharmaceutical industry. General Economics and Teaching, 405002, pp.1-24.
- Hoveling, T., Svindland Nijdam, A., Monincx, M., Faludi, J. and Bakker, C. (2024) Circular economy for medical devices: Barriers, opportunities and best practices from a design perspective. Resources, Conservation and Recycling, 208, Article 107719. doi:10.1016/j.resconrec.2024.107719
- Fox, F., Hayes, J., Whelan, B., Casey, D. & Connolly, M., 2024. Key factors impacting a medical ventilator supply chain during the COVID-19 pandemic: Lessons for pandemic preparedness. Cambridge University Press published online 12 April.
- Wu, X. and Luo, Z., 2010. Analysis on Opportunities and Challenges of Chinese Medical Device Industry under New Health Care Reform: Reference of Sweden, USA and UK.
- Dargahi, H., Darrudi, A. and Zalvand, R., 2019. Family medicine program in Iran: SWOT analysis and tows matrix model. Iranian Journal of Public Health, 48(6).
- Chaudhuri, A., 2015. Supply chain innovations in healthcare. Innovations in healthcare management: Cost-effective and sustainable solutions.
- Nze-Ekpebie, R. and Udealor, L., 2023. Global Supply Chain Effects on Medical Devices. SSRN.
- Bajada, A.J., Camillo, A.A., Erskine, A. and Holt, S., 2015. Medtronic, Inc.: Competitor's Strategic Audit, A Case Study. In Global Enterprise Management: New Perspectives on Challenges and Future Developments Volume II (pp. 153-169). New York: Palgrave Macmillan US.

Shaygan, A., Truong, J., Saglab, B.A., Selek, S., Banchongraksa, B. and Zarrin, S., 2017. Micra Transcatheter Pacing System (TPS) Tech Marketing Team Report.

Parker, T., Medtronic.

Andolina, A., Gavioli, F. and Ancarani, F., 2023. Case Study: Medtronic. H2H Marketing: Case Studies on Human-to-Human Marketing.

Daley, C., Ghahari, R.R., Drouin, M., Ahmed, R., Wagner, S., Reining, L., Coupe, A., Toscos, T. and Mirro, M., 2020. Involving patients as key stakeholders in the design of cardiovascular implantable electronic device data dashboards: Implications for patient care. *Heart Rhythm O2*, 1(2), pp.136-146.

Wu, J., Wang, Y., Tao, L., & Peng, J. (2019). Stakeholders in the healthcare service ecosystem. *Procedia CIRP*, 83, 375–379. <https://doi.org/10.1016/j.procir.2019.04.085>

Ansoff, H. I. (1957). Strategies for diversification. *Harvard Business Review*, 35(5), 113–124.

Johnson, G., Scholes, K., & Whittington, R. (2017). *Exploring Strategy: Text and Cases*. Pearson Education.

Siddiqui, M. (2021). Strategic management in healthcare: Application of growth models. *International Journal of Healthcare Management*, 14(2), 156–164.

DCF Modeling. (2024). *Medtronic plc (MDT) – Ansoff Matrix: Market Development*. [online] Available at: <https://dcfmodeling.com/products/mdt-ansoff-matrix> [Accessed 23 Jul. 2025].

Medtronic (2024) *Medtronic UK*. Available at: <https://www.medtronic.com/uk-en/index.html> (Accessed: 23 July 2025).

Medtronic. (2025, August 19). *Medtronic reports first quarter fiscal 2026 financial results*. [https://news.medtronic.com/2025-08-19-Medtronic-reports-first-quarter-fiscal-2026-financial-results\(\)](https://news.medtronic.com/2025-08-19-Medtronic-reports-first-quarter-fiscal-2026-financial-results())

Medtronic, 2025. Our Bold Ambition: To become the global leader in healthcare technology. [pdf] Available at: <https://www.medtronic.com/en-us/our-company/bold-ambition-future-of-healthcare-technology.html> [Accessed 25

Bernstein, S.L., Weiss, J. and Curry, L., 2020. Visualizing implementation: contextual and organizational support mapping of stakeholders (COSMOS).

Implementation Science Communications, 1, p.48. doi:10.1186/s43058-020-00030-8.

Scott Morton, F., 1997. Entry decisions in the generic pharmaceutical industry.

Medtronic, 2025. *Medtronic plc. Form 10-K Annual Report 2025*. Available at: https://filecache.investorroom.com/mr5ir_medtronic/829/MDT%20%28Medtronic%20plc.%29%20%20%2810-K%29%202025-06-20.pdf_.pdf [Accessed 31 July 2025].

Rizk, H.I., Elkholy, M.M., Barakat, A.A., Elsayed, R.M.M. and Abd El Fatah, S.A.M., 2021. Perspectives of pharmaceutical stakeholders on determinants of medicines accessibility at the primary care level. *Journal of Pharmaceutical Policy and Practice*, 14(1), pp.1–12. Available at: <https://doi.org/10.1186/s42506-020-00062-x>

Wu, X. and Luo, Z., 2010. Analysis on Opportunities and Challenges of Chinese Medical Device Industry under New Health Care Reform: Reference of Sweden, USA and UK.

Essay48. (n.d.). *Medtronic Porter's Diamond Model*. Available at: <https://www.essay48.com/13700-Medtronic-Porters-Diamond-Model> (Accessed: 31 July 2025).

Banga, B., 2024. *Medtronic tackles supply chain challenges in a bid to return to profitability*. Medical Technology, Issue 72 (March 2024). Available at: [online article] [Accessed 31 July 2025].

EY, n.d. *How Medtronic optimized supply chain gets products to patients in need*. Available at: https://www.ey.com/en_gl/insights/consulting/how-medtronic-optimized-supply-chain-gets-products-to-patients-in-need#:~:text=Medtronic%20turned%20to%20EY%20teams,%2C%20distribution%2C%20transportation%20and%20procurement. [Accessed 31 July 2025].

Chotia, V., Khoualdi, K., Broccardo, L. and Yaqub, M.Z., 2023. The role of cyber security and digital transformation in gaining competitive advantage through Strategic Management Accounting. *Journal of Business Research*, 162, p.113959. <https://doi.org/10.1016/j.jbusres.2023.113959>